Dr. Link is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
230 S. Main St
Suite 100
Orange, CA 92868Phone+1 714-541-0101Fax+1 714-541-0450- Is this information wrong?
Education & Training
University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 1972 - 1974
Keck School of Medicine of the University of Southern CaliforniaClass of 1972
Certifications & Licensure
CA State Medical License 1973 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- NBRST: Prospective Neo-adjuvant REGISTRY Trial Start of enrollment: 2011 Jul 01
- Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Publications & Presentations
PubMed
- 117 citationsFinal Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.Arlene Chan, Beverly Moy, Janine Mansi, Bent Ejlertsen, Frankie A. Holmes, Stephen Chia, Hiroji Iwata, Michael Gnant, Sibylle Loibl, Carlos H. Barrios, Isil Somali, Sn...> ;Clinical Breast Cancer. 2021 Feb 1
- 362 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3..., , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Oncology. 2017 Dec 1
- A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.Lawitz, E.,Freilich, B.,Link, J.,German, P.,Mo, H.,Han, L.,Brainard, D. M.,McNally, J.,Marbury, T.,Rodriguez-Torres, M.> ;J. Viral Hepat.. 2015 Jul 18
- Join now to see all
Press Mentions
Dr. John Link to Speak at Cancer Support Community PasadenaJanuary 8th, 2018
2 SCNG Columnists Among Those Honored at Long Beach Cancer League GalaJune 5th, 2023- These SCNG Columnists Are Cancer Stars. Here’s How to Hear Their StoriesJune 4th, 2023
Hospital Affiliations
Providence St. Joseph Hospital OrangeOrange, California
Children’s Health Orange County (CHOC)Orange, California- MemorialCare, Orange Coast Memorial Medical CenterFountain Valley, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
